Abstract

Studies have demonstrated that curcumin exerts its tumor suppressor function in a variety of human cancers including glioma. However, the exact underlying molecular mechanisms remain obscure. Emerging evidence has revealed that Skp2 (S-phase kinase associated protein 2) plays an oncogenic role in tumorigenesis. Therefore, we aim to determine whether curcumin suppresses the Skp2 expression, leading to the inhibition of cell growth, invasion, induction of apoptosis, and cell cycle arrest. To this end, we conducted multiple methods such as MTT assay, Flow cytometry, Wound healing assay, invasion assay, RT-PCR, Western blotting, and transfection to explore the functions and molecular insights of curcumin in glioma cells. We found that curcumin significantly inhibited cell growth, suppressed cell migration and invasion, induced apoptosis and cell cycle arrest in glioma cells. Furthermore, we observed that overexpression of Skp2 promoted cell growth, migration, and invasion, whereas depletion of Skp2 suppressed cell growth, migration, and invasion and triggered apoptosis in glioma cells. Mechanistically, we defined that curcumin markedly down-regulated Skp2 expression and subsequently up-regulated p57 expression. Moreover, our results demonstrated that curcumin exerts its antitumor activity through inhibition of Skp2 pathway. Collectively, our findings suggest that targeting Skp2 by curcumin could be a promising therapeutic approach for glioma prevention and therapy.

Highlights

  • Glioma is one of the common primary brain tumors in adults

  • To detect whether curcumin treatment inhibits cell growth in glioma cells, MTT assay was used to measure the growth viability in U251 and SNB19 cells treated with different concentrations of curcumin for 48 hours and 72 hours, respectively

  • We found that curcumin significantly inhibited cell growth in time- and dose-dependent manner in both U251 and SNB19 cells (Figure 1A)

Read more

Summary

Introduction

Glioma is one of the common primary brain tumors in adults. Due to its aggressive growth and invasion, the median survival is generally less than one and half years from the time of diagnosis [1]. Even in the favorable situations, most patients with glioma die within two years [1]. This high lethality could be due to that surgery cannot remove entire tumor without harming health brain. Standard treatment with temozolomide and radiotherapy has increased the median overall survival by 15–20 months [2]. Chemotherapy treatment needs to overcome the blood-brain barrier and drug resistance. It is necessary to discover new potential therapeutic agents for the clinical studies

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call